ABOUT US
PIPELINE
LEADING PROGRAM
TECHNOLOGY
OUR TEAM
CONTACT US
ABOUT US
PIPELINE
LEADING PROGRAM
TECHNOLOGY
OUR TEAM
CONTACT US
Leading Program
EA5: Long-Acting Subcutaneous Anti-C5 Antibody
Pipeline-in-a-Product across complement-mediated diseases
Clinical Performance
Rapid onset and durable C5 suppression with biomarker-guided dosing.
Patient Convenience
High-concentration SC formulation, injector-friendly for at-home administration.
CMC Advantages
High expression, low viscosity, scalable process with robust quality.
Commercial Positioning
Switch-friendly profile, designed for broad global partnering.
CLINICAL VALIDATION (PNH)
30
min
Free C5 to LLOQ
1
week
LDH below threshold
4
w
Maintenance dosing
9
mo+
Longest treatment
